Business Context and Reporting Period
Company: Myriad Genetics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2003 (Six months ended Dec 31, 2003 and Three months ended Dec 31, 2003)
Business Overview: Myriad is a biopharmaceutical company focused on predictive medicine products (e.g., BRACAnalysis, COLARIS) and the development of therapeutic products for cancer, Alzheimer's disease, and viral diseases. The company operates three segments: Research, Predictive Medicine, and Drug Development.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Dec 31, 2003 |
6 Months Ended Dec 31, 2003 |
6 Months Ended Dec 31, 2002 |
|---|---|---|---|
| Total Revenues | $14,148 | $27,820 | $32,529 |
| Net Loss | $(9,854) | $(19,463) | $(12,211) |
| Loss Per Share (Basic/Diluted) | $(0.36) | $(0.72) | $(0.50) |
| Operating Cash Flow | N/A | $(20,399) | $(27,371) |
| Cash & Equivalents (End of Period) | $42,464 | $42,464 | $97,027 |
| Total Assets | $156,995 | $156,995 | N/A |
| Accumulated Deficit | $(118,114) | $(118,114) | N/A |
Segment Performance (6 Months Ended Dec 31, 2003):
- Predictive Medicine: Revenue $18.5M; Operating Loss $(0.009M). Gross margin improved to 66%.
- Research: Revenue $9.3M; Operating Loss $(7.4M).
- Drug Development: Revenue $0; Operating Loss $(13.1M).
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 14% year-over-year for the six-month period ($27.8M vs. $32.5M). This was driven by a 44% drop in research revenue ($9.3M vs. $16.5M) due to the completion of collaborations with DuPont and Hitachi. Conversely, predictive medicine revenue increased 16% ($18.5M vs. $16.0M) due to wider product acceptance.
- Widening Losses: Net loss increased 59% for the six-month period ($19.5M vs. $12.2M). The increase in loss was primarily due to higher R&D costs for clinical trials and a significant legal accrual.
- Legal Accrual: Selling, general, and administrative (SG&A) expenses included a $1.8 million accrual related to an arbitration proceeding, contributing to the increase in SG&A from $17.0M to $17.6M.
- Liquidity: Cash and cash equivalents decreased by $19.1M during the six-month period. Total cash, cash equivalents, and marketable securities dropped 31% from the prior year-end ($149.1M to $103.3M) due to capital expenditures and operating losses.
Guidance, Outlook, and Risks
Outlook: Management expects to incur losses for at least the next several years due to the expansion of drug discovery, clinical trials (specifically for Flurizan/MPC-7869 in prostate cancer and Alzheimer's), and new product launches. The company believes existing capital resources are sufficient for operations for at least the next two years.
Key Risks and Contingencies:
- Arbitration Proceeding: The company is involved in an arbitration where a third party seeks approximately $5.5 million plus interest regarding marketing and licensing royalties. Myriad has accrued $1.8 million but intends to vigorously defend the claim.
- Clinical Trial Risks: Future results depend on the success of clinical trials for therapeutic candidates. Delays or failures could materially impact the business.
- Capital Requirements: The company has a shelf registration for up to $250 million in securities and intends to raise funds when conditions are favorable to meet long-term capital needs.
- Revenue Concentration: Revenue is heavily dependent on predictive medicine sales and collaborative research agreements, which can fluctuate significantly.
Investor Verification Checklist
- Arbitration Outcome: Verify the status and potential final cost of the arbitration proceeding (currently $1.8M accrued vs. $5.5M claimed).
- Clinical Trial Progress: Monitor the results of the Phase II study for Flurizan (MPC-7869) in Alzheimer's disease and the multi-center trial for prostate cancer.
- Research Revenue Pipeline: Assess the timeline for new collaborative agreements to replace the revenue lost from the completed DuPont and Hitachi projects.
- Cash Burn Rate: Track the rate of cash consumption against the $103.3M liquidity position to confirm the "two-year runway" assertion.
- Predictive Medicine Growth: Validate the sustainability of the 16% revenue growth in the predictive medicine segment given competitive pressures.